Date | Open(₹) | High(₹) | Low(₹) | Close(₹) | No. Of Trades(₹) | Total Turnover(₹) | Deliverable Quantity(₹) |
|---|---|---|---|---|---|---|---|
12-May-2025 | 4,969 | 5,065.5 | 4,935 | 5,020.5 | 18,223 | 77,79,59,041 | 48,223 |
13-May-2025 | 5,028.5 | 5,145 | 5,025 | 5,126.5 | 14,383 | 25,75,05,578.5 | 22,291 |
14-May-2025 | 5,147.5 | 5,159.5 | 5,046.5 | 5,127 | 16,788 | 53,23,70,093.5 | 61,885 |
15-May-2025 | 5,163 | 5,320.5 | 5,099 | 5,277 | 26,180 | 61,27,53,038 | 54,846 |
16-May-2025 | 5,300 | 5,316 | 5,200 | 5,221 | 22,074 | 49,03,05,122 | 40,290 |
19-May-2025 | 5,225 | 5,400 | 5,192 | 5,324 | 38,306 | 95,62,71,672.5 | 75,421 |
20-May-2025 | 5,324 | 5,374 | 5,243.5 | 5,259 | 15,736 | 36,95,82,506.5 | 32,464 |
21-May-2025 | 5,258 | 5,400 | 5,255 | 5,374 | 26,570 | 1,12,28,09,623 | 1,06,463 |
22-May-2025 | 5,384.5 | 5,388 | 5,213.5 | 5,299 | 37,660 | 1,18,72,03,800.5 | 1,16,853 |
23-May-2025 | 5,297 | 5,319 | 5,240 | 5,288 | 12,997 | 42,25,24,135.5 | 35,125 |
26-May-2025 | 5,349 | 5,367 | 5,218.5 | 5,249 | 29,056 | 63,89,73,053 | 32,650 |
27-May-2025 | 5,285 | 5,295 | 5,211 | 5,266 | 14,491 | 31,45,03,801.5 | 21,998 |
28-May-2025 | 5,266 | 5,284 | 5,214.5 | 5,264.5 | 15,085 | 41,54,99,270 | 39,896 |
29-May-2025 | 5,291 | 5,327 | 5,154 | 5,294.5 | 43,372 | 1,63,74,54,988.5 | 56,678 |
30-May-2025 | 5,110 | 5,268 | 5,043.5 | 5,098.5 | 74,106 | 3,69,75,69,846.5 | 3,95,493 |
02-Jun-2025 | 5,077 | 5,105 | 5,004 | 5,096.5 | 22,393 | 86,47,80,536.5 | 1,01,548 |
03-Jun-2025 | 5,093 | 5,118 | 4,972 | 4,996.5 | 29,263 | 84,13,45,344 | 82,780 |
04-Jun-2025 | 4,944 | 4,988 | 4,857.5 | 4,868.5 | 56,354 | 3,47,97,39,560.5 | 3,16,674 |
05-Jun-2025 | 4,869 | 4,925 | 4,826.5 | 4,843.5 | 19,262 | 73,68,35,966 | 81,651 |
06-Jun-2025 | 4,868 | 4,923 | 4,811 | 4,862.5 | 18,984 | 88,13,71,310.5 | 89,578 |
09-Jun-2025 | 4,889 | 4,890 | 4,845 | 4,873.5 | 12,126 | 40,41,77,036.5 | 41,529 |
This inspection, conducted from March 10 through March 13, 2025, was to evaluate compliance with the legal standards concerning bioequivalence studies.
The company saw its revenues increase by 1.5% YoY at ₹3,374 crore from ₹3,324 crore.
The serum contains liposomal azelaic acid, liposomal 4-butyl resorcinol, tranexamic acid, alpha arbutin, and niacinamide.
R&D expenses rose to ₹146.5 crore, making up 4.3% of total revenue, compared to ₹115.8 crore (3.4% of revenue) in the previous year.
This comes after competing private equity firms TPG Capital, Apax Partners, and KKR withdrew their original interest.
Alkem will conduct clinical trials of 'SON-080' in India, with Sonnet's support for global and local regulatory submissions.
According to sources, the floor price would be ₹5,616 per share, which is 3% lower than the current market price (CMP).
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Capital Services Support WhatsApp Number
+91 9892691696
Download The App Now
Follow us on
2025, IIFL Capital Services Ltd. All Rights Reserved
IIFL Capital Services Limited - Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
ARN NO : 47791 (AMFI Registered Mutual Fund Distributor)
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.
